CCA Summit Live from ASCO GI 2023

Stacey  Stein

CCA Summit Live from ASCO GI 2023

ASCO GI Highlights

Videos — January 26, 2023

Featuring:

Stacey Stein, MD

Associate Professor of Medicine Assistant Medical Director of the Clinical Trials Office
Leader, Hepatobiliary Program
Yale School of Medicine
Section of Medical Oncology
New Haven, CT

On January 20, 2023, I presented an overview of key abstracts on cholangiocarcinoma (CCA) presented at the 2023 annual American Society of Clinical Oncology Gastrointestinal Cancers Symposium (ASCO GI 2023). In addition, I provided my perspective on the impact of the data on the management of patients with CCA.

ASCO GI Highlights

March 2026, Vol 7, No 1

A US real-world claims database analysis demonstrated that durvalumab plus gemcitabine and cisplatin improves survival in patients with advanced biliary tract cancer.

Real-World Evidence Confirms Clinical Efficacy of Durvalumab or Pembrolizumab Plus Gemcitabine and Cisplatin in Advanced Biliary Tract Cancer

ASCO GI Highlights

March 2026, Vol 7, No 1

Real‑world outcomes show survival benefit of first-line durvalumab or pembrolizumab plus gemcitabine and cisplatin in advanced biliary tract cancer.

Tinengotinib Shows Promise in Overcoming FGFR Inhibitor Resistance in Advanced Cholangiocarcinoma

ASCO GI Highlights

March 2026, Vol 7, No 1

Tinengotinib, a novel FGFR inhibitor, has the potential to overcome resistance to prior FGFR therapies in the treatment of advanced cholangiocarcinoma.

Lirafugratinib Demonstrates Efficacy and Safety in FGFR Inhibitor–Naïve Cholangiocarcinoma Patients With FGFR2 Alterations: Phase 1/2 ReFocus Study

ASCO GI Highlights

March 2026, Vol 7, No 1

FGFR2 inhibition with lirafugratinib delivers strong responses and manageable safety in FGFR2‑altered advanced cholangiocarcinoma.

Zanidatamab Improves Survival Outcomes in HER2-Positive Biliary Tract Cancer: Post-Hoc HERIZON-BTC-01 Analysis

ASCO GI Highlights

March 2026, Vol 7, No 1

A post-hoc analysis of HERIZON-BTC-01 demonstrates improved survival outcomes in patients utilizing zanidatamab.

Safety and Preliminary Activity of Ivosidenib Plus Durvalumab With Gemcitabine and Cisplatin in IDH1-Mutant Cholangiocarcinoma: Phase 1b/2 Study Results

ASCO GI Highlights

March 2026, Vol 7, No 1

Ivosidenib in combination with durvalumab plus gemcitabine and cisplatin shows potential activity with minimal toxicity in patients with IDH1‑mutant cholangiocarcinoma.

Treatment Outcomes of IDH1-Mutant Cholangiocarcinoma in the United States: A Real-World Analysis

ASCO GI Highlights

March 2026, Vol 7, No 1

Real‑world data in IDH1‑mutant cholangiocarcinoma illuminates biomarker testing trends, treatment sequencing, and survival outcomes, outlining the role of ivosidenib in second‑line care.

Adjuvant Sintilimab Plus Capecitabine in Resected Extrahepatic Cholangiocarcinoma: Interim Results From a Phase 2 Study

ASCO GI Highlights

March 2026, Vol 7, No 1

Adjuvant sintilimab plus capecitabine shows promising recurrence‑free survival and manageable safety in resected extrahepatic cholangiocarcinoma.

Adjuvant Chemoradiation and Immunotherapy for Patients With High-Risk Resectable Extrahepatic Cholangiocarcinoma and Gallbladder Cancer: The ACCORD Trial

ASCO GI Highlights

March 2025, Vol 6, No 1

The ACCORD trial demonstrated that adjuvant chemoradiation combined with immunotherapy significantly improved survival outcomes in patients with resectable extrahepatic cholangiocarcinoma and gallbladder cancer compared with observation alone.

Durvalumab Plus Gemcitabine-Based Chemotherapy With or Without Lenvatinib for Advanced Biliary Tract Cancer: A Retrospective Study

ASCO GI Highlights

March 2025, Vol 6, No 1

A study of patients with advanced biliary tract cancer found that adding lenvatinib to durvalumab and gemcitabine-based chemotherapy improved progression-free survival, objective response rate, and disease control rate.

CCA Summit Live from ASCO GI 2023

Featuring:

Subscribe Today!

I'd like to receive:

Stay In The Know

CCA Summit Live from ASCO GI 2023

Featuring:

Related Items

Subscribe Today!

I'd like to receive:

Stay In The Know

We Value Your Feedback! Tell Us How You Consume Content